Chris Markoch

Chris Markoch

Chris Markoch is a freelance financial writer who brings over 25 years in sales and marketing to help find the story behind the stock. Chris starts by asking the question, “So what?” and then uses fundamental and (some) technical analysis to add depth to that insight.

Stepping back from the “what” allows Chris to bring perspective that helps investors make wise decisions based on their risk tolerance and investing timeline.

Markoch would describe his writing as being for investors more than traders. He looks at equities through a long-term lens and that is reflected in his writing.

In addition to his articles on InvestorPlace, you can also find Chris’ writing on MarketBeat.com where he has collaborated on the e-book “5 Investing Trends That Will Define the Market in 2022.” You can find Chris on LinkedIn and on Twitter.

Recent Articles

QuantumScape Stock Is a Tough Buy, but It May Be a Tougher Sell

Analysts are sharply divided on QS stock, so investors will have to trust their gut on this pre-revenue company.

7 Housing Stocks to Buy to Keep You Ahead of Inflation

The housing market was one of the first to show the effect of inflation on the economy. These housing stocks get ahead of that problem.

Shiba Inu Rewarded Early Investors, But Now It’s Just Another Altcoin

Belief in SHIB is belief that Shiba Inu is going to succeed where other coins have not proven they can.

Investors Losing Patience as Tilray Waits for Washington To Make Big Move

Without a clear timeline for cannabis legalization in the United States, TLRY stock is a long-term hold for only the most patient investors.

Bionano Genomics Stock Looks Ready to Reward Patient Investors

BNGO stock is down 25% since the beginning of the year. But as the company begins to deliver consistent revenue, a prudent investment may be rewarded.